Dexcom G6 CGM
subsidised for Australians with type 1 diabetes

What is a Patient Education & Awareness Program?

MedAdvisor works with industry partners and NGOs to deliver targeted communications to MedAdvisor patients with a specific disease, condition or risk factor. These direct-to-patient programs aim to provide education and awareness to help patients seek out appropriate treatment and improve their health.

Program overview

This 2-message program aims to inform patients that the Dexcom G6 Continuous Glucose Monitoring (GCM) device is subsidised for Australians with type 1 diabetes and to educate patients about the benefits of new CGM technology. 

When?

The program will commence from 4th December 2023. 

For which patients?

Patients prescribed insulin for the treatment of type 1 diabetes.

View messages

Click here to view the messages